MedTrace Logo

Post-Traumatic Stress Disorder (PTSD) and Seroquel

NCT01066156 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2017-05-30

Study results available
· View outcomes & findings →

Summary

This 8 weeks study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD.

Conditions

  • Post-Traumatic Stress Disorder

Interventions

DRUG

Seroquel

This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD

Sponsors & Collaborators

  • Cambridge Health Alliance

    lead OTHER

Principal Investigators

  • Igor Elman, MD · CHA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01066156 on ClinicalTrials.gov